Undisclosed Pipeline Assets
Ocular Diseases (e.g., Post-Surgical Inflammation/Pain)
Late Clinical StageActive
Key Facts
Indication
Ocular Diseases (e.g., Post-Surgical Inflammation/Pain)
Phase
Late Clinical Stage
Status
Active
Company
About Ocuvex Therapeutics
Ocuvex Therapeutics is a San Diego-based ophthalmology company founded in 2020, specializing in biologics and antibodies. The company has transitioned from a development-stage entity to one with a commercial product, OMLONTI®, for glaucoma, and is pursuing a pipeline targeting conditions like post-surgical inflammation. In a significant strategic move, Ocuvex has entered into a definitive merger agreement with publicly traded Onconetix, Inc., which upon closing will provide public market access and result in Ocuvex shareholders owning 90% of the combined company.
View full company profile